Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30525059 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TDP1KDM1AMAPTKDM1B | |
| SCHEMBL12378577 | 0.89 | ALDH1A1 (0.43) | ALDH1A1TDP1KDM1AMAPTKDM1B | |
| SCHEMBL13664729 | 0.86 | ALDH1A1 (0.34) | ALDH1A1TDP1KDM1AMAPTKDM1B | |
| SCHEMBL12479245 | 0.83 | ALDH1A1 (0.43) | ALDH1A1TDP1KDM1AMAPTKDM1B | |
| SCHEMBL23351729 | 0.82 | KDM1A (0.48) | ALDH1A1TDP1KDM1AMAPTKDM1B | |
| SCHEMBL14129494 | 0.82 | CA1 (0.32) | — | |
| SCHEMBL21834381 | 0.77 | GAA (0.50) | ALDH1A1TDP1KDM1AKDM1B | |
| SCHEMBL22289313 | 0.77 | AHR (0.39) | ALDH1A1TDP1KDM1AKDM1B | |
| SCHEMBL22597911 | 0.77 | ALDH1A1 (0.39) | ALDH1A1TDP1KDM1AMAPTKDM1B | |
| SCHEMBL1306767 | 0.77 | GAA (0.43) | ALDH1A1TDP1KDM1AMAPTKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025122545-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250179083-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2025-06-05 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-111601798-B | Bisamide sarcomere activating compounds and uses thereof | 美国安进公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| US-20170158668-A1 | 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2017-06-08 | — | — | US | disclosed |
| US-9409886-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2170863-B1 | Pyrimido cyclopentanes useful for the treatment of inflammatory or hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8618097-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2170863-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006567-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885TDP1 1362/4885KDM1A 1404/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885TDP1 1362/4885KDM1A 1404/4885 |
| US-20170158668-A1 | 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME | XDH, REN, BRD4 | ALDH1A1 1425/4885TDP1 3445/4885KDM1A 1314/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | ALDH1A1 2085/4885TDP1 4803/4885KDM1A 1642/4885 |
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | ALDH1A1 2573/4885TDP1 444/4885KDM1A 2865/4885 |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885TDP1 1362/4885KDM1A 1404/4885 |
| US-20250179083-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | ALDH1A1 4279/4885TDP1 639/4885KDM1A 3553/4885 |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | ALDH1A1 2573/4885TDP1 444/4885KDM1A 2865/4885 |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | ALDH1A1 2481/4885TDP1 496/4885KDM1A 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.